Aktuelle News
News Funktionen
Weitere Funktionen
23 Juni 2022
RedHill Biopharma Ltd.
RedHill Biopharma veröffentlicht Highlights aus Q1/2022: Im Plan zu einem positiven operativen Cashflow in H2/22
11 April 2022
RedHill Biopharma Ltd.
RedHill gibt effektive Hemmung der Omikron-Variante durch seinen oralen COVID-19-Wirkstoffkandidaten Opaganib in vitro bekannt
RedHill Biopharma Ltd.
RedHill gibt effektive in vitro-Hemmung der Omikron-Variante durch seinen oralen COVID-19-Wirkstoffkandidat Opaganib in vivo bekannt
15 März 2022
RedHill Biopharma Ltd.
RedHill und Kukbo unterzeichnen Lizenzvereinbarung für oral verabreichtes Opaganib zur Behandlung von COVID-19 in Südkorea
1 März 2022
RedHill Biopharma Ltd.
RedHill gibt positive Phase-2-Studienergebnisse mit oral verabreichtem RHB-107 an nicht hospitalisierten COVID-19-Patienten bekannt
17 Februar 2022
RedHill Biopharma Ltd.
RedHill Biopharma meldet Rekord-Quartalsumsatz und erreicht zum ersten Mal kommerzielle Gewinnzone
7 Februar 2022
RedHill Biopharma Ltd.
RedHill Biopharmas orales Opaganib senkt in Kombination mit Remdesivir und Kortikosteroiden die Sterblichkeitsrate bei schwerer COVID-19 um 70 %
13 Januar 2022
RedHill Biopharma Ltd.
Oral verabreichtes Opaganib von RedHill Biopharma zeigt signifikante Verbesserung der Viruselimination in Phase-2/3-Studie bei schwer erkrankten, hospitalisierten COVID-19-Patienten
13 November 2017
RedHill Biopharma Ltd.
RedHill Biopharma Reports 2017 Third Quarter Financial Results
9 November 2017
RedHill Biopharma Ltd.
RedHill Biopharma Announces Last Patient Enrolled in the Phase III Study with RHB-104 for Crohn’s Disease
2 November 2017
RedHill Biopharma Ltd.
RedHill Biopharma and IntelGenx Submit New Drug Application to FDA for RIZAPORT(R) for Migraines
26 Oktober 2017
RedHill Biopharma Ltd.
RedHill Biopharma präsentiert auf der BIO-Europe 2017
20 Oktober 2017
RedHill Biopharma Ltd.
RedHill Biopharma Receives FDA Orphan Drug Designation for MESUPRON for Pancreatic Cancer
3 Oktober 2017
RedHill Biopharma Ltd.
RedHill Biopharma Announces Positive Top-Line Results from Phase II Study of BEKINDA(R) in Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
2 Oktober 2017
RedHill Biopharma Ltd.
RedHill Biopharma Accelerates RHB-104 Phase III Study in Crohn’s Disease with Top-Line Results Expected Mid-2018
18 September 2017
RedHill Biopharma Ltd.
RedHill Biopharma Receives Notice of Allowance for a New U.S. Patent Covering its Combination Therapy for Hard-to-Treat Cancers
13 September 2017
RedHill Biopharma Ltd.
RedHill Biopharma Ltd.: RedHill Biopharma Initiates Promotion of Esomeprazole Strontium Delayed-Release Capsules 49.3 mg in the U.S
17 August 2017
RedHill Biopharma Ltd.
RedHill Biopharma Announces U.S. Commercialization Agreement for FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules :
10 August 2017
RedHill Biopharma Ltd.
RedHill Biopharma Provides 2017 Semi-Annual Business Update
31 Juli 2017
RedHill Biopharma Ltd.
RedHill Biopharma Announces Unanimous Positive DSMB Recommendation for Continuation of the Phase III Study with RHB-104 for Crohn’s Disease
25 Juli 2017
RedHill Biopharma Ltd.
RedHill Biopharma Reports 2017 Second Quarter Financial Results
17 Juli 2017
RedHill Biopharma Ltd.
RedHill Biopharma Announces Last Patient Visit in BEKINDA(R) Phase II Study for IBS-D
12 Juli 2017
RedHill Biopharma Ltd.
RedHill Biopharma Announces Expected Timeline for DSMB meeting and Provides Updated on Enrollment in the RHB-104 Phase III Study for Crohn’s Disease
15 Juni 2017
RedHill Biopharma Ltd.
RedHill Biopharma Announces Confirmatory Phase III Study Initiated with RHB-105 (TALICIA(TM)) for H. pylori Infection
14 Juni 2017
RedHill Biopharma Ltd.
RedHill Biopharma Announces Successful Phase III Top-Line Results with BEKINDA(R) for Acute Gastroenteritis
13 Juni 2017
RedHill Biopharma Ltd.
RedHill Biopharma Initiates Promotion of Donnatal(R) and EnteraGam(R) in the U.S.
3 Mai 2017
RedHill Biopharma Ltd.
RedHill Biopharma Reports 2017 First Quarter Financial Results
24 April 2017
RedHill Biopharma Ltd.
RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA(R) Phase II Study for IBS-D
18 April 2017
RedHill Biopharma Ltd.
RedHill Biopharma Receives Notice of Allowance for Two Additional U.S. Patents Covering BEKINDA(R)
5 April 2017
RedHill Biopharma Ltd.
RedHill Biopharma Announces Exclusive U.S. License from Entera Health for Commercial GI Product EnteraGam(R)